Trial Profile
A population-based cohort comparative study of two formulations of Tiotropium (Handihaler vs Respimat) in patients with Chronic Obstructive Pulmonary Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2016
Price :
$35
*
At a glance
- Drugs Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 13 Nov 2016 New trial record